Arrowhead Pharmaceuticals' stock rallied 17% due to significant pipeline developments and strategic partnerships. Learn more ...
Stocktwits on MSN4h
Arrowhead, Sarepta Stocks Rise Despite Price-Target Cuts Post $1B Licensing Deal: Retail Buzz Strong($ARWR) and Sarepta Therapeutics Inc. ($SRPT) climbed on Wednesday despite Wall Street trimming price targets after the ...
A broad licensing and research alliance will hand Sarepta four clinical-stage candidates, while Arrowhead receives $500 ...
GlobalData on MSN14h
Arrowhead and Sarepta link for rare genetic disease treatmentsArrowhead Pharmaceuticals has entered a worldwide licensing and partnership agreement with Sarepta Therapeutics to develop ...
Sarepta Therapeutics is paying Arrowhead Pharmaceuticals $500 million in cash, plus a $325 million equity investment, for ...
Arrowhead (ARWR) announced a global licensing and collaboration agreement with Sarepta (SRPT). Upon closing, Arrowhead will receive $825M, consisting of $500M cash and $325M as an equity investment ...
Sarepta Therapeutics said it will pay Arrowhead Pharmaceuticals $500 million in cash for a series of experimental RNA-based ...
Sarepta Therapeutics (SRPT), the leader in precision genetic medicine for rare diseases announced an exclusive global licensing and collaboration agreement with Arrowhead (ARWR) Pharmaceuticals ( ARWR ...
Arrowhead Pharmaceuticals (ARWR) stock surges 21% in premarket after $825M licensing deal with Sarepta (SRPT) for rare ...
After Sarepta (SRPT) announced a global licensing and collaboration agreement with Arrowhead (ARWR) that adds four clinical-stage siRNA assets ...
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) shares are trading higher Tuesday after the company announced a global ...
Needham lowered the firm’s price target on Sarepta (SRPT) to $202 from $205 and keeps a Buy rating on the shares. The deal with Arrowhead ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback